Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Capital Employed: 2020-2025

Historic Return on Capital Employed for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to 0.06%.

  • Keros Therapeutics' Return on Capital Employed rose 48.00% to 0.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06%, marking a year-over-year increase of 48.00%. This contributed to the annual value of -0.45% for FY2024, which is 9.00% up from last year.
  • Keros Therapeutics' Return on Capital Employed amounted to 0.06% in Q3 2025, which was up 14,067.27% from 0.00% recorded in Q2 2025.
  • Keros Therapeutics' Return on Capital Employed's 5-year high stood at 0.06% during Q3 2025, with a 5-year trough of -0.52% in Q4 2023.
  • Its 3-year average for Return on Capital Employed is -0.31%, with a median of -0.40% in 2023.
  • Per our database at Business Quant, Keros Therapeutics' Return on Capital Employed declined by 19bps in 2022 and then spiked by 48bps in 2025.
  • Quarterly analysis of 5 years shows Keros Therapeutics' Return on Capital Employed stood at -0.24% in 2021, then decreased by 19bps to -0.44% in 2022, then fell by 9bps to -0.52% in 2023, then increased by 16bps to -0.37% in 2024, then skyrocketed by 48bps to 0.06% in 2025.
  • Its last three reported values are 0.06% in Q3 2025, 0.00% for Q2 2025, and -0.02% during Q1 2025.